For patients with recurrent pregnancy loss
Immunotherapy for unexplained recurrent miscarriage
In 1981, immunotherapy with the husband's lymphocytes was used for the treatment of unexplained recurrent miscarriage. Initially, it was speculated that the closer the HLA antigen match between husband and wife, the more effective the immunotherapy would be. In other words, the theory was that if the HLA antigens were similar, the fetal antigens would not be recognized within in the uterus and the immunological pregnancy maintenance mechanism would not be established, thereby avoiding repeated miscarriage. Nagoya City University was also the first institution in Japan to successfully perform immunotherapy in 1983, and became well known for its work in the field of RPL. Although this theory was later rejected, immunotherapy has been used for about 20 years in Japan and other countries. However, in 1999, a double-blind randomized trial showed that immunotherapy was ineffective, with a birth rate comparable to that of saline, and the American FDA recommended that immunotherapy using a husband's lymphocytes "not be used except for research purposes" because of the risk of infection and a host-versus-host graft reaction. We have also heeded this warning and do not currently offer immunotherapy.
Index
- Definition of recurrent miscarriage and recurrent pregnancy loss and results of the Japan Environment and Children’s Study (JECS)
- Examination and causes of RPL
- Antiphospholipid syndrome
- ー
- Treatment of antiphospholipid syndrome
- Chromosomal translocation in either partner
- Preimplantation genetic testing for chromosomal structural rearrangement
- Congenital uterine anomaly
- Thrombotic predisposition
- Endocrine abnormality
- Fetal or embryonic aneuploidy
- Preimplantation genetic testing for aneuploidy
- Immunotherapy for unexplained recurrent miscarriage
- Drug administration for repeated miscarriages of unknown cause
- Unknown Causes
- Emotional support
- References
